0.00Open0.85Pre Close0 Volume1 Open Interest2.50Strike Price0.00Turnover468.71%IV26.67%PremiumDec 20, 2024Expiry Date0.25Intrinsic Value100Multiplier10DDays to Expiry0.60Extrinsic Value100Contract SizeAmericanOptions Type-0.3987Delta0.2199Gamma2.65Leverage Ratio-0.0343Theta-0.0004Rho-1.06Eff Leverage0.0014Vega
MediciNova Stock Discussion
13 mins ago
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
No comment yet